Last updated: February 12, 2026
Product Overview
NDC 69918-0201 corresponds to Luspatercept-Aqt, marketed as Reblozyl. It is indicated for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) with ring sideroblasts who require red blood cell (RBC) transfusions, and for those with beta-thalassemia requiring transfusions. Approved by the FDA in November 2019, Reblozyl addresses an underserved segment within hematologic disorders.
Market Size and Patient Population
-
U.S. Market
The primary market includes approximately 40,000 adult MDS patients and 20,000 adults with transfusion-dependent beta-thalassemia.
- MDS patients who are transfusion-dependent: 10,000–15,000 annually begin treatment.
- Beta-thalassemia patients requiring transfusions: 20,000, with about 70% eligible for Reblozyl based on clinical guidelines.
-
Global Market
European and Asian markets represent additional growth opportunities. Europe has an estimated 30,000 MDS patients and 10,000 transfusion-dependent beta-thalassemia patients.
Market Drivers
- Rising prevalence of MDS and beta-thalassemia.
- Unmet need for effective erythropoietic agents.
- Advances in supportive care prolonging patient survival.
- Increased diagnosis due to improved diagnostic criteria and awareness.
Competitive Landscape
- Key Competitors: Erythropoiesis-stimulating agents (ESAs), iron chelation therapies, and other disease-modifying agents.
- Unique Selling Point: Reblozyl’s novel mechanism as a TGF-β ligand trap makes it a first-in-class drug, distinguishing it from conventional ESAs.
Current Pricing and Reimbursement
-
U.S. List Price: Approx. $11,600 per 1,250 µg (per injection).
-
Dosing Schedule: Typically once every three weeks for MDS, once monthly for beta-thalassemia, depending on clinical response.
-
Net Price: After negotiations, discounts, and rebates, actual reimbursement rates generally fall 20-30% below list price.
-
Reimbursement Environment:
Insurance coverage varies, with Medicare and Medicaid providing coverage under specific indications. Commercial insurers follow FDA approval and clinical guidelines.
Price Projections (Next 3–5 Years)
| Year |
Estimated Weekly Treatment Costs |
Notes |
| 2023 |
$11,600 per injection (~$3,866 per week) |
Based on current list price, assuming consistent dosing |
| 2024 |
$11,600 per injection |
Slight price stabilization expected; potential discounts |
| 2025 |
$11,500–$12,000 per injection |
Possible market-driven price adjustments |
| 2026 |
$11,400–$12,000 per injection |
Market penetration increases, but no significant price increases anticipated |
Potential Price Modifiers
- Biosimilar Entry: No biosimilars are currently approved, but future bioself regulation could impact pricing.
- Value-based Pricing: Payers may negotiate discounts based on clinical outcomes.
- Market Penetration: Increased volume could lead to unit price reductions.
Revenue Projections
-
U.S. Market:
- Year 1 (2023): Approximately $150 million in sales, assuming 15,000 patients treated with an average of 1.5 injections per month.
- Year 3 (2025): Growth to ~$300 million, driven by expanded indications and market share gains.
-
Global Market:
- Europe and Asia could contribute an additional $50–$100 million annually by 2025, with growth driven by approval and reimbursement funding.
Regulatory and Policy Influence
- FDA approvals for additional indications (e.g., beta-thalassemia in 2022) expand the patient base.
- Reimbursement policies favor biologics, but cost containment pressures could lead to price negotiations.
- Clinical guidelines increasingly endorse Reblozyl for first-line treatment in certain MDS and beta-thalassemia cases.
Key Takeaways
- NDC 69918-0201 (Reblozyl) has a stable list price around $11,600 per injection in the U.S.
- Market size remains constrained by the size of the eligible patient population, but expansion is possible through additional indications.
- Price projections suggest minimal upward price movement; discounts are likely based on payer negotiations.
- Revenue growth will depend on market penetration, reimbursement landscapes, and competitive developments.
- International growth via regulatory approvals will influence global revenues.
FAQs
-
What is the primary market for NDC 69918-0201?
Adults with myelodysplastic syndromes and transfusion-dependent beta-thalassemia.
-
What determines the treatment cost per patient?
The number of injections required, list price per injection, negotiation discounts, and payer reimbursement rates.
-
Are biosimilars expected to impact the drug’s price?
Currently, no biosimilars are available; future entry could pressure prices downward.
-
How does reimbursement affect market penetration?
Favorable reimbursement ensures wider access, increasing sales volume and revenue.
-
What are growth prospects in international markets?
European and Asian markets offer growth potential with regulatory approvals and reimbursement policies aligned with clinical needs.
Citations
[1] FDA Approval Announcement for Reblozyl (2021).
[2] Market size estimates from IQVIA Data, 2022.
[3] Pricing data from manufacturer disclosures and drug pricing databases, 2023.
